FLC
ORIAW

Fifth Lane Capital’s Orion Biotech Opportunities Corp. Warrant ORIAW Stock Holding History

Fifth Lane Capital’s Portfolio ORIAW Stock Details ORIAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,849
Closed -$4K – 412
2021
Q4 		$4K Buy
+3,849
New +$4.02K ﹤0.01% 296

Other funds holding ORIAW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Fifth Lane Capital's ORIAW Position: Q1 2022 in Review

Fifth Lane Capital sold out of Orion Biotech Opportunities Corp. Warrant (ORIAW) in Q1 2022, closing a stake of 3,849 shares — an estimated $4K sold.

Fifth Lane Capital first reported a position in ORIAW in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 30 funds tracked by Wall St. Rank hold ORIAW as of Q1 2022.

  • Fifth Lane Capital reported no remaining Orion Biotech Opportunities Corp. Warrant position as of Q1 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 3,849 Orion Biotech Opportunities Corp. Warrant shares in Q1 2022, an estimated $4K.
  • Fifth Lane Capital first reported a position in Orion Biotech Opportunities Corp. Warrant in Q4 2021 and held it in 1 quarter.
  • Fifth Lane Capital's Orion Biotech Opportunities Corp. Warrant position peaked at $4K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Warrant as of Q1 2022.

Based on Fifth Lane Capital's 13F filing for Q1 2022, filed 16 May 2022.